Edition:
United States

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

50.97USD
19 Jun 2018
Change (% chg)

$0.20 (+0.39%)
Prev Close
$50.77
Open
$50.49
Day's High
$51.65
Day's Low
$50.49
Volume
341,931
Avg. Vol
380,204
52-wk High
$71.22
52-wk Low
$41.16

Select another date:

Thu, Apr 26 2018

BRIEF-Alkermes Q1 GAAP Loss Per Share $0.40

* Q1 REVENUE $225.2 MILLION VERSUS I/B/E/S VIEW $219.3 MILLION

BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461

* ALKERMES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER

BRIEF-Alkermes Says CEO's FY 2017 Total Compensation Was $9.4 Mln VS $9.6 Mln In FY 2016

* ALKERMES PLC SAYS CHAIRMAN AND CEO RICHARD POPS' FY 2017 TOTAL COMPENSATION WAS $9.4 MLN VS $9.6 MLN IN FY 2016 - SEC FILING Source text: (https://bit.ly/2GPYT4o) Further company coverage:

BRIEF-Alkermes CEO Says Does Not Believe Additional Trials Of Depression Drug Necessary

* CEO SAYS "WE DON'T BELIEVE ANY ADDITIONAL CLINICAL TRIALS ARE NECESSARY" ON CONF CALL WHEN ASKED ABOUT FDA'S DECISION ON ITS DEPRESSION DRUG‍​ Further company coverage:

FDA refuses to review Alkermes' depression treatment, seeks more trials

Alkermes Plc has been told to conduct more clinical trials of its experimental depression treatment after the U.S. Food and Drug Administration rejected its initial application for approval, citing a lack of evidence of its effectiveness.

UPDATE 3-FDA refuses to review Alkermes' depression treatment, seeks more trials

* Shares fall as much as 22 percent (Adds comments from conference call; updates shares)

FDA rejects application to review Alkermes' depression treatment

April 2 Alkermes Plc said on Monday the U.S. Food and Drug Administration rejected the application seeking approval for its experimental depression drug, citing insufficient evidence of effectiveness.

BRIEF-Alkermes Receives Refusal To File Letter From FDA For ALKS 5461

* ALKERMES RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR ALKS 5461

BRIEF-Alkermes Says Co, Units Entered Amendment To Amended And Restated Credit Agreement

* ALKERMES PLC SAYS ON MARCH 26, CO ,UNITS ENTERED AMENDMENT TO AMENDED & RESTATED CREDIT AGREEMENT, DATED AS OF SEPTEMBER 16, 2011 - SEC FILING

BRIEF-Alkermes Appoints James Robinson As President And Chief Operating Officer

* ALKERMES APPOINTS JAMES ROBINSON AS PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Select another date: